Huntsman Cancer Institute Receives NIH Grant for Clinical Trial of Curacyte's PHP
Curacyte AG and its wholly-owned subsidiary, Apex Bioscience, Inc. have announced that the Huntsman Cancer Institute (HCI) Multidisciplinary melanoma Translational Research Program has received notice of funding by the NIH for National Institutes of Health R21 Quick Trial Award - Clinical trial of PHP with high-dose interleukin-2 (IL-2),. This study is designed to test Curacyte's experimental drug, PHP, in patients receiving melanoma and kidney cancer treatment with IL-2. Laboratory studies at the HCI of the mechanism of IL-2 side effects identified this drug as a promising means of counteracting low blood pressure and "vascular leak syndrome" that currently limit IL-2-based cancer treatment.
Curacyte's PHP is a scavenger of nitric oxide (NO), the main causative agent responsible for vasodilation and hypotension in distributive shock. PHP has been demonstrated to reverse the vasodilation and resolve the hypotension associated with distributive shock. PHP has completed Phase II clinical studies in distributive shock and is entering a Phase III study. Additional clinical studies of PHP in patients with cardiogenic shock are also planned.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.